Enhertu

Enhertu tops standard care in first-line HER2 lung cancer trial

AstraZeneca and Daiichi Sankyo announced on Monday that their antibody drug conjugate Enhertu demonstrated a statistically significant improvement in progression-free survival over the current global standard of care as a first-line treatment for patients with HER2-mutant advanced lung cancer, marking…